Swiss National Bank Avrobio, Inc. Transaction History

Swiss National Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$3.45 - $6.05 $276,345 - $484,605	-80,100 Closed	0 $0
Q4 2020 Feb 05, 2021	BUY	$12.79 - $17.1 $240,451 - $321,480	18,800 Added 30.67%	80,100 $1.12 Million
Q3 2020 Nov 09, 2020	BUY	$12.99 - $19.41 $12,990 - $19,410	1,000 Added 1.66%	61,300 $798,000
Q2 2020 Aug 05, 2020	BUY	$12.19 - $22.96 $96,301 - $181,384	7,900 Added 15.08%	60,300 $1.05 Million
Q1 2020 May 08, 2020	BUY	$10.08 - $27.21 $100,800 - $272,100	10,000 Added 23.58%	52,400 $815,000
Q4 2019 Feb 06, 2020	BUY	$13.05 - $21.88 $36,540 - $61,264	2,800 Added 7.07%	42,400 $854,000
Q3 2019 Nov 12, 2019	BUY	$14.12 - $23.44 $307,816 - $510,992	21,800 Added 122.47%	39,600 $559,000
Q2 2019 Aug 02, 2019	SELL	$13.21 - $27.29 $81,902 - $169,198	-6,200 Reduced 25.83%	17,800 $289,000
Q1 2019 May 10, 2019	BUY	$12.46 - $22.05 $166,964 - $295,470	13,400 Added 126.42%	24,000 $529,000
Q4 2018 Feb 13, 2019	BUY	$15.43 - $32.7 $163,558 - $346,620	10,600 New	10,600 $176,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.